Page 11234..10..»

Archive for the ‘Neuropathy’ Category

Cardiac Autonomic Neuropathy Treatment Market: Expansion Strategies Set to Generate Substantial Revenue in the near Future – Eurowire

Sunday, October 25th, 2020

The latest published an effective statistical data titled as Cardiac Autonomic Neuropathy Treatment Market. It defines about the recent innovations, applications and end users of the market. It covers the different aspects, which are responsible for the growth of the industries. Different domains are considered on the basis of the capital of Cardiac Autonomic Neuropathy Treatment market. The analyst examines different companies on the basis of their productivity to review the current strategies. All leading players across the globe, are profiled with different terms, such as product types, industry outlines, sales and much more.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2817289&source=atm

The study throws light on the recent trends, technologies, methodologies, and tools, which can boost the performance of companies. For further market investment, it gives the depth knowledge of different market segments, which helps to tackle the issues in businesses. It includes effective predictions about the growth factors and restraining factors that can help to enlarge the businesses by finding issues and acquire more outcomes. Leading market players and manufacturers are studied to give a brief idea about competitions. To make well-informed decisions in Cardiac Autonomic Neuropathy Treatment areas, it gives the accurate statistical data.

The analyst also focuses on economic and environmental factors, which impacts on the growth of the businesses. For global analysis, the market is examined by considering the different regions such as North America, Latin America, Japan, China, and India. Leading companies are focusing on spreading their products across the regions. Research and development activities of the various industries are included in the report, to decide the flow of the market.

segment by Type, the product can be split intoSolid OralInjectable

Market segment by Application, split intoHospitalsCardiac CentersAmbulatory Surgical Centers

Based on regional and country-level analysis, the Cardiac Autonomic Neuropathy Treatment market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2817289&source=atm

Competition Analysis

This report examines the ups and downs of the leading key players, which helps to maintain proper balance in the framework. Different global regions, such as Germany, South Africa, Asia Pacific, Japan, and China are analyzed for the study of productivity along with its scope. Moreover, this report marks the factors, which are responsible to increase the patrons at domestic as well as global level.

In the competitive analysis section of the report, leading as well as prominent players of the global Cardiac Autonomic Neuropathy Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyPfizerRoche HoldingNovartisAmgenPrivi PharmaSilverline ChemicalsAnthem BiopharmaPraxis Pharmaceutical

It gives a detailed description of drivers and opportunities in Cardiac Autonomic Neuropathy Treatment market that helps the consumers and potential customers to get a clear vision and take effective decisions. Different analysis models, such as, Cardiac Autonomic Neuropathy Treatment are used to discover the desired data of the target market. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2817289&licType=S&source=atm

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cardiac Autonomic Neuropathy Treatment market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Cardiac Autonomic Neuropathy Treatment Market Analysis, Trends, Growth Factor

Chapter 5 Cardiac Autonomic Neuropathy Treatment Market Application and Business with Potential Analysis

Chapter 6 Global Cardiac Autonomic Neuropathy Treatment Market Segment, Type, Application

Chapter 7 Global Cardiac Autonomic Neuropathy Treatment Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Cardiac Autonomic Neuropathy Treatment Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

More:
Cardiac Autonomic Neuropathy Treatment Market: Expansion Strategies Set to Generate Substantial Revenue in the near Future - Eurowire

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Increase Exponentially During 2020 2027 – Eurowire

Sunday, October 25th, 2020

Latest added Global Chemotherapy Induced Peripheral Neuropathy Treatment Market research study offers detailed product outlook and elaborates market review till 2025. The market Study is segmented by key regions that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

This report studies the Global Chemotherapy Induced Peripheral Neuropathy Treatment market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Chemotherapy Induced Peripheral Neuropathy Treatment market by companies, region, type and end-use industry.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/14077

to Avail deep insights of Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2017-2019), Segment Revenue Market Share (%) by Players (2017-2019) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Competitive Analysis:

The major players are focusing highly on innovation in technologies to improving efficiency level. The industry growth outlook is captured by ensuring ongoing process improvements of players and optimal strategies taken up by companies to fight COVID-19 Situation.

The following players are covered in this report:

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Solasia Pharma K.K.

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/14077

Market Segments: The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market has been divided into type, application, and region.

Breakdown Data by Type

Calcium Channel 2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Based on regional and country-level analysis, the Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

On The basis of region, the Chemotherapy Induced Peripheral Neuropathy Treatment is segmented into countries, with production, consumption, revenue (million USD), and market share and growth rate in these regions, from 2014 to 2025 (forecast), see highlights below

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/14077

What we can offer in the Strategic Opportunities

We analysts identify in broad terms why some companies are gaining or losing share within a given market segment. Every company have its own story and changes in market share are knowingly the most important indicator of management effectiveness & corporate strategies; it is important to identify those who are succeeding in the market and those who are failing, and the cause of the market flux. Key Financial Ratios are also considered to get towards root-cause analysis of each companies such as Return on Assets, ROCE, and Return on Equity etc. From this understanding of the forces driving the market, the analyst team prepares its strategic recommendations. Ultimately, its that market wisdom, beyond the market data and forecasts, which is the most valuable component of market research studies and provides our clientele with the greatest competitive edge with top level quality standards.

How insights and forecasts from the reports could benefit you:

More here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market to Increase Exponentially During 2020 2027 - Eurowire

Read More...

5 Reasons Rehabilitation Care is Important After Breast Cancer – University of Michigan Health System News

Sunday, October 25th, 2020

Many patients think of cancer care as chemotherapy or surgery to remove a tumor or mass. But, there is one important treatment that is often overlooked: rehabilitation.

Breast cancer, in particular, can leave many patients with painful symptoms and side effects that rehabilitation could help ease.

Weve noticed that many patients with breast cancer have greatly benefited from the rehabilitation care we can provide, says Sean Smith, M.D., an associate professor of physical medicine and rehabilitation at Michigan Medicine and medical director of the Cancer Rehabilitation Program at the University of Michigan Rogel Cancer Center.

The Cancer Rehabilitation Program offers patients, with any type of cancer, at any point in treatment, comprehensive rehabilitation services and care.

One of our most robust programs for patients with breast cancer is the lymphedema program, which involves hands-on therapy by specialty-trained occupational therapists, Smith says. But, we also see a lot of patients greatly improve from symptoms such as pain in the shoulder and chest, and stiffness from aromatase inhibitors, or medications that stop the production of estrogen in postmenopausal women.

Smith says many patients with breast cancer often dont realize rehabilitation care is available for them, and that its performed by experts specifically trained to help the patient group.

The expertise for rehabilitating cancer patients at Michigan Medicine is matched by few institutions, he says. Patients coming here can be sure that they will receive a thorough, detailed and individualized approach to their care by people who understand the complicated and difficult medical treatment they have received.

Here, Smith highlights five reasons why rehabilitation care is important for patients with breast cancer.

1. Rehabilitation care helps to treat the physical and mental side effects of cancer.

Smith says the most common reason for rehabilitation care in patients with breast cancer is chest or shoulder issues after surgery and radiation. This can include pain, tightness, numbness and more.

We also diagnose and treat problems related to chemotherapy, including neuropathy or cognitive issues, aromatase inhibitors, such as stiffness, pain and trigger finger, and the disease itself, such as back pain and cognitive issues with metastatic disease, he says.

The team helps with both the physical aspects of rehabilitation, such as a patient needing supportive braces or having a tough time reaching overhead due to tightness from radiation therapy, as well as the cognitive side effects of cancer treatment.

We help patients that have neuropathy from chemotherapy and we provide options for treatment including balance therapy, Smith says. We also help treat chemobrain, or what patients often describe as a mental cloudiness or cognitive impairment from chemotherapy.

2. Cancer rehabilitation care is specialized to the patients specific needs.

The Cancer Rehabilitation Program practices what they call impairment-driven cancer rehabilitation.

Thats a complicated way of saying we treat whatever problem a patient describes, Smith says. For example, if a patient wants to be able to throw a ball with her grandchild, we work on that. Our program is always 100% patient-centered and individualized to their needs.

Smith says the cancer rehabilitation team includes physicians, physical and occupational therapists, psychologists and additional experts, to address whichever needs a patient is experiencing.

The physicians are cancer rehabilitation physicians, which means that they sub-specialize in treating neurologic, musculoskeletal and cognitive problems that patients experience due to cancer treatment, he says. Our therapists often receive additional certifications to be able to best treat cancer-related issues, including lymphedema, radiation fibrosis and more.

3. Rehabilitation care benefits patients at any point along their cancer treatment timeline.

Whether a patient is currently going through breast cancer treatment, or is in remission, the cancer rehabilitation team is ready to help.

We treat patients all along the cancer treatment timeline from those newly diagnosed, to those who have been free of disease for decades, to those with metastatic disease, Smith says. Before we meet a patient, we conduct a thorough review of their cancer treatment history so that we are prepared to make a plan after talking with the patient.

4. Patients dont need a referral to see a rehabilitation specialist.

Making an appointment with a cancer rehabilitation specialist at Michigan Medicine can be done a couple of ways.

Often times, patients are referred by one of their oncology providers to see either a physician, therapist or psychologist, Smith says. Of course we also have patients call for an appointment without a referral, which is great, too.

He notes that once a patient sees one member of the team, they are sometimes referred to another provider if it would help in their overall treatment.

A physician might refer a patient for lymphedema therapy, or a therapist may suggest a referral to a psychologist if the patient is struggling with cognitive issues, Smith says.

5. Adding rehabilitation care to cancer treatment can benefit a patients quality of life.

Patients who are treated for cancer often are assumed to be back to normal when their treatment ends, but Michigan Medicine and the U-M Rogel Cancer Center recognize that is not the case, Smith says. Its not uncommon for patients to be dealing with the after effects of cancer treatment long after treatment ends.

The rehabilitation team of experts can help restore a patients quality of life, no matter what type of cancer they are experiencing. Smith says the goal is always to get the patient back to doing what they enjoy, whether that be spending time with their family, returning to work or keeping up with their hobbies.

He adds, Patients with breast cancer, or any form of cancer, don't have to endure these issues, but they often don't know how to get help or the amount of help that is available to them. They can take the first step by contacting our team, or asking their doctor for a referral. We would love to meet with them and develop a plan to help them recover from cancer-related symptoms.

Learn more about the Cancer Rehabilitation Program and schedule an appointment.

The rest is here:
5 Reasons Rehabilitation Care is Important After Breast Cancer - University of Michigan Health System News

Read More...

Diabetes mellitus in an adolescent girl with intellectual disability caused by novel single base pair duplication in the PTRH2 gene: Expanding the…

Sunday, October 25th, 2020

This article was originally published here

Brain Dev. 2020 Oct 19:S0387-7604(20)30272-2. doi: 10.1016/j.braindev.2020.09.009. Online ahead of print.

ABSTRACT

BACKGROUND: Infantile-onset multisystem neurologic, endocrine, and pancreatic disease (IMNEPD) is an extremely rare autosomal recessive disorder with variable expressivity, caused by biallelic mutations in the PTRH2 gene. Core features are global developmental delay or isolated speech delay, intellectual disability, sensorineural hearing loss, ataxia, and pancreatic insufficiency (both exocrine and endocrine). Additional features may include postnatal microcephaly, peripheral neuropathy, facial dysmorphism, and cerebellar atrophy. In literature, there are only a few anecdotal case reports and none of the previous cases presented with diabetic ketoacidosis.

METHODS: We are reporting a 12-year old adolescent girl with mild intellectual disability who presented with fever, pain abdomen for 2 days, and fast breathing for one day.

RESULTS: Her random blood sugar was 472 mg/dl and arterial blood gas revealed high anion gap metabolic acidosis. Urine examination showed ketonuria. On further evaluation, she was found to have demyelinating sensorimotor polyneuropathy and sensorineural hearing loss. Neuroimaging and other ancillary investigations were normal. Whole exome sequencing revealed a novel homozygous single base pair duplication in exon 1 of the PTRH2 gene (c.127dupA, p.Ser43LysfsTer11), confirming the diagnosis of IMNEPD.

CONCLUSIONS: Apart from describing a novel single base pair duplication causing protein truncation in the PTRH2 gene for the first time, our case also expanded the clinical spectrum of IMNEPD, as this is the first case with seemingly pure neurodevelopmental phenotype, who later developed diabetes mellitus, without any exocrine pancreatic abnormality. IMNEPD should be considered in children or adolescents with global developmental delay or intellectual disability when they develop diabetes mellitus.

PMID:33092935 | DOI:10.1016/j.braindev.2020.09.009

Read more here:
Diabetes mellitus in an adolescent girl with intellectual disability caused by novel single base pair duplication in the PTRH2 gene: Expanding the...

Read More...

MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center,…

Friday, October 23rd, 2020

LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled, randomized Phase 2b trial to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy (CIPN).

The clinical trial is a collaborative effort between MediciNova, the University of Sydney, and the Australasian Gastro-Intestinal Trials Group (AGITG). Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney in Australia, will be the lead principal investigator. The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment to reduce acute neurotoxicity severity and CIPN in patients with metastatic colorectal cancer. AGITG will provide funding for this study and MediciNova will provide study drug and regulatory support.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, We are excited to collaborate with Dr. Vardy on this grant-funded study to further explore the potential of MN-166 as a pharmacotherapy for CIPN. As we recently reported, our first clinical trial in CIPN showed that half of participants reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment. There is a large unmet medical need for patients with this disorder.

Dr. Janette Vardy, the Principal Investigator for this study, commented, The findings from our initial study were encouraging, and with the support of AGITG and MediciNova, we plan to explore further the potential clinical utility of ibudilast in a larger sample of patients who experience oxaliplatin-induced acute neurotoxicity and chronic CIPN.

About the Chemotherapy-induced Peripheral Neuropathy Trial

This study is a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial to determine whether MN-166 (ibudilast) can decrease acute neurotoxicity symptoms and CIPN, and to determine whether ibudilast treatment results in fewer neurotoxicity-induced dose reductions in patients with metastatic colorectal cancer receiving oxaliplatin up to six months. We plan to enroll a total 100 patients in a 1:1 (ibudilast:placebo) ratio. Treatment (MN-166 (ibudilast) 60 mg/day or matching placebo) will commence two days prior to the first cycle of oxaliplatin chemotherapy and will continue for the duration of the oxaliplatin chemotherapy.

About Chemotherapy-induced Peripheral Neuropathy

Peripheral neuropathy is a set of symptoms caused by damage to the nerves that are outside of the brain and spinal cord. These distant nerves are called peripheral nerves. Some of the chemotherapy and other drugs used to treat cancer can damage peripheral nerves that carry sensations to the hands and feet. This damage results in chemotherapy-induced peripheral neuropathy (CIPN) and is a common side effect of cancer chemotherapy. Most commonly, people complain of pins and needles in their toes and fingers. CIPN may affect cancer outcomes due to reductions in chemotherapy dosing and/or premature treatment discontinuation and have a profound impact on quality of life and survivorship. According to a meta-analysis which included more than 4,000 patients, CIPN prevalence was 68% when measured in the first month after chemotherapy, 60% at 3 months, and 30% at 6 months or more (Seretny et al., 2014). Long-term neurotoxicity is an important issue for the growing number of cancer survivors, with the highest number of affected patients having been treated for breast and/or colon cancer.

About MN-166 (ibudilast)

MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. Our earlier human studies demonstrated significant reductions of serum MIF level after treatment with MN-166 (ibudilast). It also attenuates activated glial cells, which play a major role in certain neurological conditions. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies, which provide the rationale for treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS) and other neurological diseases such as glioblastoma (GBM), and substance abuse/addiction. MediciNova is developing MN-166 for ALS, progressive MS and other neurological conditions such as degenerative cervical myelopathy (DCM), glioblastoma, substance abuse/addiction, and chemotherapy-induced peripheral neuropathy, as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19. MediciNova has a portfolio of patents which covers the use of MN-166 (ibudilast) to treat various diseases including ALS, progressive MS, and drug addiction.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNovas pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit http://www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," considering, planning or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Read more here:
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center,...

Read More...

Consumers Opting For To Help The Neuropathic Pain Market Cross US$ 10414.0 Mn Between 2024 – The Think Curiouser

Friday, October 23rd, 2020

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

The rest is here:
Consumers Opting For To Help The Neuropathic Pain Market Cross US$ 10414.0 Mn Between 2024 - The Think Curiouser

Read More...

Diabetic Peripheral Neuropathy Treatment Market to Witness Huge Growth by 2028 | Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc – Eurowire

Friday, October 23rd, 2020

A new research study from JCMR with title Global Diabetic Peripheral Neuropathy Treatment Market Research Report 2029 provides an in-depth assessment of the Diabetic Peripheral Neuropathy Treatment including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies & strategies. The research study provides forecasts for Diabetic Peripheral Neuropathy Treatment investments till 2029.

The report does include most recent post-pandemic market survey on Diabetic Peripheral Neuropathy Treatment Market.

Competition Analysis : Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd

Request Free PDF Sample Report @: jcmarketresearch.com/report-details/1142321/sample

Commonly Asked Questions:

At what rate is the market projected to growThe year-over-year growth for 2020 is estimated at XX% and the incremental growth of the market is anticipated to be $xxx million.

Get Up to 40 % Discount on Enterprise Copy & Customization Available for Following Regions & Country: North America, South & Central America, Middle East & Africa, Europe, Asia-Pacific

Who are the top players in the market?Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd

What are the key market drivers and challenges?The demand for strengthening ASW capabilities is one of the major factors driving the market.

How big is the North America market?The North America region will contribute XX% of the market share

Enquiry for segment [emailprotected] jcmarketresearch.com/report-details/1142321/enquiry

This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations

Geographical Analysis:

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.

Europe: UK, France, Italy, Germany, Spain, and Russia.

Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Market Analysis by Types: Antimunocel, ASP-8477, BNV-222, Capsaicin, CBX-129801, Others

Market Analysis by Applications: Hospital, Clinic, Others

Some of the Points cover in Global Diabetic Peripheral Neuropathy Treatment Market Research Report is:

Chapter 1: Overview of Global Diabetic Peripheral Neuropathy Treatment Market (2013-2025) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2013 and 2018 Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2013-2018) Sales Revenue and market share

Chapter 4, 5 and 6: Global Diabetic Peripheral Neuropathy Treatment Market by Type, Application & Players/Suppliers Profiles (2013-2018) Market Share by Type & Application Growth Rate by Type & Application Drivers and Opportunities Company Basic Information

Continue

Note: Please Share Your Budget on Call/Mail We will try to Reach your Requirement @ Phone: +1 (925) 478-7203 / Email: [emailprotected]

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us: https://jcmarketresearch.com/contact-us

JCMARKETRESEARCH

Mark Baxter (Head of Business Development)

Phone: +1 (925) 478-7203

Email: [emailprotected]

Connect with us at LinkedIn

Read the rest here:
Diabetic Peripheral Neuropathy Treatment Market to Witness Huge Growth by 2028 | Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc - Eurowire

Read More...

Neuropathy Pain Treatment Market 2020 SWOT Analysis By Major Eminent Vendors: Pfizer, Depomed, Eli Lilly – The Think Curiouser

Friday, October 23rd, 2020

Research Reports Inc furnishes the newest report on Neuropathy Pain Treatment marketing research and Forecast 2020-2025, outlining key insights and presenting a competitive advantage to clients through a comprehensive report. This report analyses the Neuropathy Pain Treatments industry coverage, current market competitive status, and market outlook and forecast by 2025. Global Neuropathy Pain Treatment players, to explain, define and analyze the worth, market competition landscape, market share, SWOT analysis, and development plans within the future comprise a number of the key features, within the report.

Click Here To Access The Sample Report: http://www.researchreportsinc.com/report-sample/921265

(Use Corporate eMail ID So Immediately Accessible With Higher Priority.)

Global Neuropathy Pain Treatment Market Research Report compiles the newest industry data, key players analysis, market share, rate of growth, opportunities and trends, investment strategy for your reference in analyzing the worldwide market. Many companies are operating within the market and overseeing their businesses through joint ventures, which is probably going to profit the general market.

The Major Key Players Covered In This Report:

Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

The Neuropathy Pain Treatment report covers the following Types:

On the basis of applications, the market covers:

The report segments the market into various sub-segments, thereby encompassing the overall market. The approximations of the revenue numbers for the entire market and its sub-segments are also additionally incorporated during this report. Moreover, the report highlights variety of the most growth prospects, including new product launches, R&D, M&A, collaborations, joint ventures, agreements, partnerships, and growth of the key players operating within the Neuropathy Pain Treatment market. It determines the factors that are directly influencing the market which comprises production strategies and methodologies, development platforms, and thus the merchandise model.

Geographically Regions covered in this report:

Grab Your Report at an Impressive Discount @ http://www.researchreportsinc.com/check-discount/921265

Report Highlights:

The global Neuropathy Pain Treatment market size is predicted to realize huge market traction within the forecast period of 2020 to 2025. The Neuropathy Pain Treatment market report provides an in-depth analysis of worldwide market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players. Regional analysis is another highly comprehensive part of the research and analysis segment of the worldwide Neuropathy Pain Treatment market presented within the report. Research Reports Inc analysts understand competitive strengths and supply competitive analysis for every competitor separately.

Go here to read the rest:
Neuropathy Pain Treatment Market 2020 SWOT Analysis By Major Eminent Vendors: Pfizer, Depomed, Eli Lilly - The Think Curiouser

Read More...

Edited Transcript of NURO.OQ earnings conference call or presentation 22-Oct-20 12:00pm GMT – Yahoo Finance

Friday, October 23rd, 2020

Q3 2020 NeuroMetrix Inc Earnings Call WALTHAM Oct 22, 2020 (Thomson StreetEvents) -- Edited Transcript of NeuroMetrix Inc earnings conference call or presentation Thursday, October 22, 2020 at 12:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Shai N. Gozani NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary * Thomas T. Higgins NeuroMetrix, Inc. - Senior VP, CFO & Treasurer ================================================================================ Conference Call Participants ================================================================================ * Jarrod M. Cohen JM Cohen & Company - MD * William Church ================================================================================ Presentation -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- Good morning, and welcome to the NeuroMetrix Third Quarter 2020 Earnings Call. My name is Shannon, and I will be your moderator on the call. On this call, the company may make statements which are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature that depend upon or refer to future events or conditions are forward-looking statements. Any forward-looking statements reflect current views of NeuroMetrix about future results of operations and other forward-looking information. You should not rely on forward-looking statements because actual results may differ materially as a result of a number of important factors, including those set forth in the earnings release issued earlier today. Please refer to the risks and uncertainties, including the factors described under the heading Risk Factors in the company's periodic filings with the SEC available on the company's Investor Relations website at neurometrix.com and on the SEC's website at sec.gov. NeuroMetrix does not intend and undertakes no duty to update the information disclosed on this conference call. I'd now like to introduce the NeuroMetrix Senior Vice President and Chief Financial Officer, Mr. Thomas Higgins. Mr. Higgins? -------------------------------------------------------------------------------- Thomas T. Higgins, NeuroMetrix, Inc. - Senior VP, CFO & Treasurer [2] -------------------------------------------------------------------------------- Thank you, Shannon. I'm joined on the call by Dr. Shai Gozani, our President and Chief Executive Officer. NeuroMetrix develops and commercializes neurostimulation-based medical devices for the diagnosis and treatment of chronic health conditions. Our commercial products are DPNCheck, ADVANCE and Quell. DPNCheck is a point-of-care test for the detection of peripheral neuropathies. ADVANCE is a point-of-care device that provides neuro conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. And Quell is a wearable mobile app-enabled neurostimulation device indicated for symptomatic relief and management of chronic pain. It is available over the counter. Q3 was a good quarter for the company, particularly considering the larger economic environment and the operating constraints imposed by managing the business with employee safety as the top priority. We experienced a rebound in customer orders from the second quarter of 2020. Production was busy throughout Q3 and facility utilization was necessarily high to address customer needs. Our operating activities, that is R&D, sales and marketing and G&A, were all tightly managed. The forward outlook remains unclear. We appreciate the customer demand levels, raw material supply and staffing issues all have a high degree of uncertainty. However, the business performance in Q3 leaves us with a sense of optimism as we enter the last quarter of the year. Turning to our operating results in Q3, which we reported earlier today. Total revenue was about $2 million. DPNCheck orders were strong in the quarter for both devices and biosensors. Demand in the Medicare Advantage sector from new accounts as well as long-standing customers led the way. Our Japanese business with Fukuda Denshi also contributed meaningfully to the quarter results. The ADVANCE diagnostic business rebounded from the depressed levels of Q2, and Quell contributed revenue and product line profitability. Our gross profit on revenue was $1.5 million. This was a gross margin rate of 73.6%. The strong margin level was an encouraging outcome from our efforts at targeting a sustainable margin of 70% plus going forward. Lower indirect production costs and higher throughput contributed to the margin. OpEx spending totaled just under $1.8 million. This level of spending has been consistent over the past 2 quarters, and it's about 1/3 below Q3 of 2019. The current spending level is sustainable going forward. R&D spending of $652,000 was about flat with the prior quarter and 37% higher than Q3 2019. It reflected R&D activity with a primary focus on the next-generation DPNCheck technology for release next year 2021. Sales and marketing spending of $340,000 was down 47% from Q3 of last year. And G&A spending of $762,000 was down 48% from Q3 of last year and reflects reduced professional services. Our net loss for the year was -- for the quarter was $257,000. This was an improvement of $1.1 million or 82% improvement versus Q3 2019 net loss of $1.4 million. On a per share basis, the Q3 2020 loss was $0.07 per share versus a loss of $1.44 per share in Q3 last year. Cash at the end of Q3 was $4.9 million, an amount sufficient to fund the company's operations into and likely through Q4 of 2021. Our capital structure is debt-free. There are about 3.8 million common shares outstanding. With that, let me turn this over to Dr. Gozani, who will now address our overall strategy. -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [3] -------------------------------------------------------------------------------- Thank you. As Tom outlined, we are pleased with the company's performance in the third quarter. So I'll take this opportunity to review our business strategy, which is built around 3 principles. The first is that we have prioritized attainment of profitability. This past quarter was encouraging in this respect as we reported an operating loss of about $250,000. We have established an efficient cost structure throughout the business. This covers headcount, manufacturing, marketing and distribution, which has led to lower operating expenses and improving gross margins. I should point out that our ability to realize these efficiencies is a testament to the commitment and talent of our employees. Because of the overall economic uncertainty and the need to get more experience with our business initiatives, we are not currently positioned to state a specific crossover quarter into profitability at this time. The second principle in our strategy is innovation. Our corporate mission is to bring innovative health care products to our customers that improve their health and quality of life. Our products are unquestionably the most advanced in their categories, whether that is neuropathy diagnostics or TENS devices. We have and will continue to maintain our historical focus and investment in R&D. The recent example is our launch of the Quell Watch app, the first smartwatch app to control a wearable pain relief device. Also, as we have previously announced, we are updating all elements of the DPNCheck system, which includes the device itself, the consumable biosensor and the associated reporting software. We recently launched the updated biosensor and expect to release the new software, which includes enterprise and data security features that our large Medicare Advantage customers are requesting. We expect to launch that before the end of the year. And the last principle in our strategy is maintaining a dynamic market strategy. We believe that achieving profitability and leveraging our industry-leading innovation requires a flexible strategy. By that, I mean that we need to be nimble in finding the best opportunities for our products. This is most clearly manifested in Quell, where we have defined 4 core clinical indications. The current application for Quell is lower extremity chronic pain, primarily knee pain, which affects up to 25% of adults in the U.S. Quell is particularly well suited to this application because of its typical placement near the knee and its novel wearable design that enables user activity. We have identified 3 additional indications that we plan to develop: fibromyalgia, chemotherapy-induced peripheral neuropathy or CIPN and restless leg syndrome or RLS. In combination, these conditions represent a market of 10 million to 20 million individuals in the U.S. We have pilot or randomized controlled trial data on all 3 with our fibromyalgia program the furthest along. We hope to announce program updates in the second half of next year. In summary, NeuroMetrix has novel products that are targeting large markets. We are committed and operationally efficient organization that is structured to support growth and move towards profitability. That completes our prepared comments, and we'd be happy to take any questions at this point. ================================================================================ Questions and Answers -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- (Operator Instructions) Our first question comes from Jarrod Cohen with JM Cohen & Company. -------------------------------------------------------------------------------- Jarrod M. Cohen, JM Cohen & Company - MD [2] -------------------------------------------------------------------------------- Yes. Just a quick question. It's been, I guess, what, 5 years since you've launched the Quell. And I'm just curious what your opinion is in terms of why haven't you seen more reoccurring revenue from the gel packs. Since I think you have, what, a little over 200,000 -- you sold a little bit over 200,000 Quell devices in the 5 years since then. -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [3] -------------------------------------------------------------------------------- Yes. That's correct, Jarrod. We have -- we've shipped around 200,000 devices over -- it's about 5.5 years now. Yes, I think there's -- we do have a recurring revenue stream from our Quell customers. And as you might expect in a consumer-oriented product, you are going to have churn and trail off of customers over time. Many customers use our product for a period of time. It helps them. They move -- they potentially don't need it anymore or they come back and forth or they go on to alternative therapy. So it's a fairly dynamic situation. I would say, overall, I would agree with you that we're not -- we're a little bit disappointed overall in the consistency of the recurring revenue stream from the consumables and are -- in fact, I think our moving-forward strategy is somewhat reflective of that, where we're focused on more specific indications that I think we can build better connections to the consumers and better serve their needs to get a stronger recurring revenue and more consistent recurring revenue stream. But I think, overall, the answer to your question is there are many reasons, some of which are expected and some of which I think we're somewhat disappointed. But we do have a consistent revenue stream from those customers and continue to see that, but we need to improve on it. -------------------------------------------------------------------------------- Jarrod M. Cohen, JM Cohen & Company - MD [4] -------------------------------------------------------------------------------- Okay. Because you don't give an exact -- but do you see from the existing installed base, about 25% of them coming back to you or even less than that? You don't give an exact number, I know that, but I'm just curious at this point in the life cycle. -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [5] -------------------------------------------------------------------------------- Yes. I don't have a good number to give you in that respect, and I think it's kind of a complicated situation. So I don't want to quote a number. Also for competitive reasons, we tend to be fairly subdued on what we describe. But it really depends. I mean, there's a wide variation among customers. I think it needs to be improved, clearly. And again, by being more focused on specific indications that allow us to build more specific services and support setting to the app and to our customer service for those applications, I think we'll strengthen that going forward. -------------------------------------------------------------------------------- Operator [6] -------------------------------------------------------------------------------- (Operator Instructions) Our next question comes from Bill Church with Tgra. -------------------------------------------------------------------------------- William Church, [7] -------------------------------------------------------------------------------- DPNCheck, how much market share growth is in front of us that we see going forward? -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [8] -------------------------------------------------------------------------------- Well, we have no -- so that's a good question. I mean the -- there is no competition, so we're the only player in peripheral neuropathy diagnostics at the point of care. So I think there's tremendous opportunity in terms of what the overall market. I mean we're at a fairly early stage, even in terms of our core effort in Medicare Advantage. So I would say that there is significant growth opportunities. We're probably at less than, I would say, what, 5% to 10% of the -- even Medicare Advantage opportunity, which is our core focus in the U.S. and even at lower percentages in international markets, so tremendous growth. Now I want to point out, I mean, this is an emerging concept for many plans and insurers to screen for peripheral neuropathy. So while the opportunity is quite large, there's a lot of education that has to go along with that, but the opportunity is quite impressive. -------------------------------------------------------------------------------- William Church, [9] -------------------------------------------------------------------------------- So how do we realize that? Or I know you've got the new software update coming and that sort of thing. But it's just getting the word out, I guess, or be improved for insurance plans and so forth? -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [10] -------------------------------------------------------------------------------- Well, in the U.S., our core focus is on Medicare Advantage accounts. We are in the 2 largest Medicare Advantage insurers in the country. So we've -- over the last 4, 5 years have become sort of standard of care within those insurers. And as they are expanding their footprint, as they are implementing programs, we tend to go along with that. It's not -- it's difficult to push the growth at the rate we'd like to see, because we're dealing with very large organizations, and they tend to develop relatively slowly. So it is getting the word out. It's providing the right kind of software to integrate into their enterprise solutions, and it's growing along with them and growing along with the Medicare Advantage business overall. So to your point, I mean, yes, we try to get the word out. We try to provide the right support. We'd obviously like to see it grow faster, but there is a pace to it that we have to appreciate. -------------------------------------------------------------------------------- Operator [11] -------------------------------------------------------------------------------- (Operator Instructions) I'm currently showing no further questions at this time. I'd like to turn the call back over to Dr. Gozani for closing remarks. -------------------------------------------------------------------------------- Shai N. Gozani, NeuroMetrix, Inc. - Founder, Chairman, CEO, President & Secretary [12] -------------------------------------------------------------------------------- Thank you, and we appreciate you joining us on this call today and look forward to updating you early next year. -------------------------------------------------------------------------------- Operator [13] -------------------------------------------------------------------------------- Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.

Continued here:
Edited Transcript of NURO.OQ earnings conference call or presentation 22-Oct-20 12:00pm GMT - Yahoo Finance

Read More...

Fact.MR Report: What is the impact of Coronavirus on Diabetic Neuropathy Market Growth – The Cloud Tribune

Thursday, October 22nd, 2020

Fact.MRhas come up with a study on Diabetic Neuropathy Market and the report is laden with information that can be utilized by stakeholders in the market to make informed decisions. Analysts have widely utilized the well-entrenched and effective market intelligence tools to collect and collate and then present the analysis and assessment of the Diabetic Neuropathy Market in an easily understandable format for all. The report includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis and Porters five forces investment return data, and investment feasibility analysis. The global Diabetic Neuropathy market Demand has seen a historical CAGR of nearly XX% during the period (2015-2019) and is projected to create a valuation of about US$ XX Mn/Bn by 2025.

The Diabetic Neuropathy Market report offers an in-depth analysis of the cost structure, market size, and PESTEL analysis which offers market outlook. Likewise, the Diabetic Neuropathy Market report focuses on the major economies across the globe.

The COVID-19 pandemic has dramatically changed the dynamics of the Diabetic Neuropathy Market. This market research report includes extensive data on the impacts of the market. The research analyst team of the firm has been monitoring the market during this coronavirus crisis and has been talking with the industry experts to finally publish a detailed analysis of the future scope of the Diabetic Neuropathy Market. They have followed a robust research methodology and got involved in primary and secondary research to prepare the Diabetic Neuropathy Market report.

For Right Perspective & Competitive Insights on Diabetic Neuropathy Market, Request for a Sample:

https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

Analysts have made use of varied industry-wide prominent tools of market intelligence to gather, collate, and analyze market data, figures, and facts to arrive at revenue estimations and projections in the Diabetic Neuropathy Market.

The research report of the Diabetic Neuropathy Market comprises significant insights for the clients and vendors that are looking to maintain their market position as well as to expand the business in the current and upcoming market scenarios. Furthermore, the report provides a detailed study of the facts and figures, as viewers search for the scope in market growth related to the category of the product.

Competitive Landscape:

Major players in the market are identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top manufacturers; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market shares, growth rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

Market Segmentation:

The common characters are also being considered for segmentation such as global market share, common interests, worldwide demand, and supply of Diabetic Neuropathy Market.

On the basis of end-use industry, the global Diabetic Neuropathy market report offers insights into the opportunities and new avenues of following key segments:

In order to analyze growth prospects in the aforementioned segments in the global Diabetic Neuropathy market, the study assesses demand and consumption patterns of the following product segments

We offer tailor-made solutions to fit your requirements, request customization @

https://www.factmr.com/connectus/sample?flag=RC&rep_id=4698

To have a better understanding of regional dynamics, the Global Diabetic Neuropathy Market covers the following geographies:

How can Fact.MR Make a Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release-

https://www.factmr.com/media-release/1608/diabetic-neuropathy-market-trends

The rest is here:
Fact.MR Report: What is the impact of Coronavirus on Diabetic Neuropathy Market Growth - The Cloud Tribune

Read More...

Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 – TechnoWeekly

Thursday, October 22nd, 2020

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Cardiac Autonomic Neuropathy Treatment market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Cardiac Autonomic Neuropathy Treatment market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Cardiac Autonomic Neuropathy Treatment market to assist our clients arrive at beneficial business decisions.

The Cardiac Autonomic Neuropathy Treatment market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Cardiac Autonomic Neuropathy Treatment market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

What pointers are covered in the Cardiac Autonomic Neuropathy Treatment market research study?

The Cardiac Autonomic Neuropathy Treatment market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Cardiac Autonomic Neuropathy Treatment market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Cardiac Autonomic Neuropathy Treatment market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Cardiac Autonomic Neuropathy Treatment market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Cardiac Autonomic Neuropathy Treatment market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Cardiac Autonomic Neuropathy Treatment market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

Some of the Major Highlights of TOC covers:

See the original post:
Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 - TechnoWeekly

Read More...

Lilly Announces Agreement to Acquire Disarm Therapeutics – PRNewswire

Thursday, October 22nd, 2020

INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 15, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in preclinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Axonal degeneration is a common, yet unaddressed, pathology in a broad range of neurological diseases and is known to cause severe sensory, motor, and cognitive symptoms. Disarm's scientific founders, Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University School of Medicine in St Louis, discovered that the SARM1 protein is a central driver of axonal degeneration. Disarm's SARM1 inhibitors are designed to directly prevent the loss of axons.

Under the terms of the agreement, Lilly will acquire Disarm for an upfront payment of $135.0 million. Disarm equityholders may be eligible for up to $1.225 billion in additional future payments for potential development, regulatory and commercial milestones should Lilly successfully develop and commercialize new medicines resulting from the acquisition.

"Lilly continues to seek medicines to treat the debilitating pain and loss of function associated with nerve damage," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration. We will move quickly to develop their SARM1 inhibitors into potential medicines for peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis."

"Disarm's innovative approach to treating axonal degeneration holds tremendous promise for addressing a wide spectrum of neurological diseases, and we have made significant strides toward enabling potentially transformative therapies," said Alvin Shih, M.D., Chief Executive Officer of Disarm. "Lilly is ideally suited to advance this exciting new approach to treating axonal degeneration, and we look forward to seeing patients benefit from the work that Disarm initiated." Disarm was founded by Atlas Venture, Drs. Milbrandt and DiAntonio of Washington University School of Medicine in St. Louis, and Atlas Entrepreneurs-in-Residence Dr. Rajesh Devraj and Dr. Raul Krauss. Lightstone Ventures and AbbVie Ventures co-invested with Atlas to support the foundational work at Disarm.

This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

Aquilo Partners, L.P. acted as financial advisor and WilmerHale LLP as legal advisor to Disarm on this transaction.

About Disarm TherapeuticsDisarm Therapeutics is a biotechnology company that is creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disability and disease progression. By inhibiting the SARM1 protein, identified by the company's scientific founders as the central driver of axonal degeneration, these therapeutics may prevent the loss of axons in chronic and acute diseases of the central, ocular, and peripheral nervous systems. For a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, the therapeutic goal is to prevent further degeneration, stabilize disease, and allow for functional recovery.

AboutEli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com. C-LLY

Lilly Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Disarm Therapeutics ("Disarm"), and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the transactionand in the process of drug development and commercialization. Among other things, there can be no guarantee that the transaction will be completed in the anticipated timeframe, or at all, or that the conditions required to complete the transaction will be met, that Lilly will realize the expected benefits of the acquisition, or that the acquisition will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Refer to:Mark Taylor; [emailprotected]; (317) 276-5795 (Lilly Media)Kevin Hern; [emailprotected];(317) 277-1838 (Lilly Investors)Stephanie Simon; [emailprotected]; (617) 581-9333 (Disarm Media)

SOURCE Eli Lilly and Company

lilly.com

See the article here:
Lilly Announces Agreement to Acquire Disarm Therapeutics - PRNewswire

Read More...

Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer – Targeted Oncology

Thursday, October 22nd, 2020

Several late-phase results were shared during the European Society of Medical Oncology (ESMO) Virtual Congress in gynecologic malignancies, but the data presented generated excitement about the number of novel options for patients after initial treatment.

Updated findings in ovarian cancer demonstrated continued benefit for PARP inhibition as maintenance therapies following frontline treatment in advanced ovarian cancer in the phase 3 SOLO-1 trial (NCT01844986) using the PARP inhibitor olaparib (Lynparza) and in the phase 2 PRIMA/ENGOT-OV26/GOG-3012 ([PRIMA], NCT02655016), which utilized the PARP inhibitor niraparib (Zejula).

Enthusiasm also surrounded a potential new approach in cervical cancer from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study ([innovaTV], NCT03438396), which explored treatment with the investigational antibody-drug conjugate tisotumab vedotin.

The longest duration of follow-up for any PARP inhibitor in the previously untreated advanced ovarian cancer setting was performed in the phase 3, randomized, double-blind, placebo-controlled, multicenter SOLO-1 trial, in which olaparib maintenance was given to patients with BRCA mutations. The 5-year follow-up results were presented at ESMO by Susan Banerjee, MD, PhD, FRCP, consultant medical oncologist and research lead for the Gynecology Unit at The Royal Marsden.1

The updated analysis after 5 years of follow-up shows that the benefit of olaparib continues substantially beyond the end of treatment, Banerjee told Targeted Oncology in an interview.

Out of the 391 patients assessed, 260 received olaparib maintenance and 131 received placebo for up to 2 years or until progressive disease (PD). Olaparib maintenance first demonstrated an improvement in progression-free survival (PFS) in the primary analysis with the median PFS not yet reached in the olaparib arm at this timepoint compared with 13.8 months in the placebo arm (HR, 0.30; 95% CI, 0.23-0.41).

The median follow-up for the updated analysis was 4.8 years in the olaparib arm compared with 5.0 years in the placebo arm. The results showed PFS events in 45% of the olaparib-treated population versus 76% of the placebo population. The median PFS observed with olaparib maintenance was 56.0 months compared with 13.8 months in the placebo arm (HR, 0.33; 95% CI, 0.25-0.43).

These are very encouraging results that will help us explain the potential benefits of maintenance olaparib in patients with BRCA mutations, said Banerjee.

A new analysis of the phase 3 randomized, double-blind, placebo-controlled, multicenter PRIMA trial presented during ESMO by GiorgioValabrega, MD, investigated the potential difference in efficacy and safety by age of niraparib maintenance after chemotherapy in patients with advanced ovarian cancer.

The key findings of our trial were that there is no difference in terms of safety and efficacy by adding niraparib to chemotherapy. Also, the [adverse events] that were observed in patients above 65 and 75 [years of age] in comparison to younger patients are not different, Valabrega, associate professor, University of Torino School of Medicine, told Targeted Oncology in an interview.

The subanalysis included 444 patients from the original PRIMA study who were 65 years of age or younger. Of the patients included in this analysis, 297 received niraparib and 147 received placebo.2

A second cohort from the analysis included 289 patients aged 65 or older. Among this group, 76 patients were 75 years or older. One hundred ninety of the patients received niraparib maintenance while 99 received placebo in the younger cohort and of those 75 years or older, 54 patients received niraparib and 22 received placebo.

Demonstrating consistency with the primary analysis which showed a median PFS on 13.8 months with niraparib compared with 8.2 months in the placebo arm, niraparib maintenance prolonged PFS compared with placebo in this subanalysis. In the patients under the age of 65, the median PFS was 13.9 months with niraparib versus 8.2 months with placebo (HR, 0.61; 95% CI, 0.47-0.81). Patients aged 65 or older had a median PFS of 13.7 months with niraparib versus 8.1 months with placebo (HR, 0.53; 95% CI, 0.39-0.74). In the 75 years of age or below group, niraparib led to a median PFS of 13.8 months compared with placebo, which had a median PFS of 8.2 months (HR, 0.62; 95% CI, 0.50-0.77). Finally, in patients aged 75 of older, the median PFS was 13.8 months with niraparib versus 5.6 months with placebo (HR, 0.37; 95% CI, 0.17-0.81).

Both ages groups were similar in terms of the number percentage of treatment-emergent adverse events (TEAEs) observed. The most common treatment-emergent TEAEs were anemia, leukopenia and hypertension. Notably, patients aged 65 years or older experienced a small increase in thrombocytopenia during treatment as did those aged 75 years of age or older. The rates of 3 TEAEs were also similar between the age groups.

Results from the single-arm, multicenter, international phase 2 study innovaTV were presented during ESMO by Robert Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network. The result of the study was that treatment with tisotumab vedotin led to antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.3

We basically confirmed the responses that we saw in the first-in-human phase 1 and 2 study with a 24% response rate, Coleman told Targeted Oncology.

Importantly, 7% of those patients had complete response, which, for those of who have treated this disease, these are not common findings, he added.

As Coleman shared, the objective response rate observed in the trial was 24% (95% CI, 15.9%-33.3%), with complete responses in 7% of the population, partial respondes in 17%, and stable disease in 49%. In terms of PD, 24% of patients progressed on treatment. The median duration of response observed with tisotumab vedotin was 8.3 months (95% CI, 4.2 to not reached). Notably, the treatment also led to a decrease in target lesion size in 79% of the patients who received tisotumab vedotin when compared with their baseline measurements.

Among the confirmed responders, the median time to response was 1.4 months (range, 1.1-5.1). It was also noted during Colemans ESMO presentation that responses were seen across the subgroup populations explored, regardless of tumor histology, lines of prior therapy, or responses to prior treatment.

The median PFS achieved with tisotumab vedotin was 4.2 months (95% CI, 3.0-4.4). At 6 months, the PFS rate was 30% (95% CI, 20.8%-40.1%). The median overall survival with the agent was 12.1 months (95% CI, 9.6-13.9) and the 6-month OS rate was 79% (95% CI, 69.3%-85.6%).

Treatment-related AEs (TRAEs) occurred in greater than 10% of the study population. The majority of the (TRAEs) observed in this study were grade 1 and 2 in severity. The most TRAEs of any grade were alopecia (38%), epistaxis (30%), nausea (27%), conjunctivitis (26%), and fatigue (24%). One patient in the died as a results of treatment-related septic shock.

Ocular, bleeding, and neuropathy TRAEs were also assessed in the study and bleeding TRAES were most prevalent, with grade 1 events having observed in 34% of patients. Ocular TRAEs were the second most prevalent with grade 1 events having occurred in 25% of patients. Finally, grade 1 peripheral neuropathy occurred in 17% of patients.

Data from this study led to the conclusion that tisotumab vedotin is a potential new treatment option for patients with previously treated recurrent of metastatic cervical cancer.

References:

1. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020. Virtual. Abstract 811M0.

2. Valabrega G, Pothuri B, Oaknin A, et al. Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract 819P.

3. Coleman RL, Larusso D, Gennigens C, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract LBA32.

Original post:
Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer - Targeted Oncology

Read More...

The Senior Hour – Getting Real Results Treating Neuropathy – 09/23/2020 – KHTS Radio

Tuesday, September 29th, 2020

If you or a senior you know needs help during this time, please do not hesitate to call the SCV Senior Center at (661) 259-9444. You can also visit their website by clicking here. They remain dedicated to doing everything they can to help while following the latest guidelines from the CDC and LA County Health Officials.

Hosts: Dr. Gene Dorio & Barbara Cochran

Topic:Getting Real Results Treating Neuropathy

Guests:Dr. Thomas Polucki, DC

Click here to listen to the full show!

Right click here to download the podcast and take it with you!

Join Barbara Cochran and Dr. Gene Dorio every Wednesday from 11 a.m. to Noon on your Hometown Station KHTS 98.1 FM & AM 1220 for The Senior Hour, your home for Senior Care and Lifestyle.

On this episode of The Senior Hour with Dr. Gene Dorio and Barbara Cochran, Dr. Thomas Polucki, DC, comes in to the studio to talk about getting real results treating neuropathy. To participatein a free telehealth webinar on peripheral neuropathy hosted by Dr. Polucki, you can register by clicking here.If you would like to schedule an appointment with Dr. Thomas Polucki or find out more about the services he offers, you can do so on his website by clicking here.

Listen to the full show by downloading the podcast by clicking on the links above and by listening on Facebook at KHTS Radio or by clicking the Play button in the box below!

The Senior Hour 09/23/20

It's time for this week's episode of The Senior Hour with Dr. Gene Dorio and Barbara Cochran. On this episode, Dr. Thomas Polucki, DC, joins Barbara and Dr. Dorio in the studio.

Posted by KHTS Radio on Wednesday, September 23, 2020

Barbara Cochran has been a resident of the Santa Clarita Valley for over 40 years and has spent much of that time volunteering with and creating a variety of organizations. The 1983 SCV Woman of the Year brings senior news to you every week on your Hometown Station.

Dr. Gene Dorio, M.D. has practiced Internal Medicine in the SCV since 1988. A member of the medical staff at Henry Mayo Newhall Memorial Hospital, he is very active in local senior affairs.

As Santa Claritas only local radio station, KHTS broadcasts a combination of news, traffic, sports, and features along with your favorite adult contemporary hits.Santa Clarita news and featuresare delivered throughout the day over our airwaves, on our website and through a variety of social media platforms. Our KHTS national award-winning daily news briefs are now read daily by 34,000+ residents. A vibrant member of the Santa Clarita community, the KHTS broadcast signal reaches all of the Santa Clarita Valley and parts of the high desert communities located in the Antelope Valley. The station streams its talk shows over the web, reaching a potentially worldwide audience.Follow @KHTSRadio onFacebook,Twitter, andInstagram, and sign up forKHTS email and text alertstoday!

Follow this link:
The Senior Hour - Getting Real Results Treating Neuropathy - 09/23/2020 - KHTS Radio

Read More...

Diabetic Neuropathy Market Expected to accelerate the growth of the industries forecast 2020-2026 – The Daily Chronicle

Tuesday, September 29th, 2020

The Diabetic Neuropathy Market report defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the market and also highlights the key changing course adopted by the companies to maintain their strength. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and commination of key companies are altogether referenced in the report. Every single leading player in this global market are profiled with details such as product types, business overview, sales, manufacturing base, contestant, applications, and specifications.

Diabetic Neuropathy Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast. The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

Free Sample Report + All Related Graphs & Charts: @ https://www.coherentmarketinsights.com/insight/request-sample/213

Manufacturer Detail: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

This Diabetic Neuropathy research report includes a close on these trends, share, size which will facilitate the companies in operation within the trade to work out the market and strategize for his or her business development consequently. The analysis report analyses the expansion, market size, key segments, trade share, application, and key drivers.

Regional Analysis ForDiabetic Neuropathy Market

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Diabetic Neuropathy Market Research Methodology :

This study estimates it provides a detailed qualitative and quantitative analysis of the Diabetic Neuropathy market. Primary sources, such as experts from related industries and suppliers of Diabetic Neuropathy were interviewed to obtain and verify critical information and assess prospects of the Diabetic Neuropathy market

Key players within the Diabetic Neuropathy market are known through secondary analysis, and their market shares are determined through primary and secondary analysis. All activity shares split, and breakdowns are resolute victimization secondary sources and verified primary sources. The Diabetic Neuropathy Market report begins with a basic summary of the trade lifecycle, definitions, classifications, applications, and trade chain structure and every one these along can facilitate leading players to perceive the scope of the Market, what characteristics it offers and the way itll fulfill customers needs.

Get Discount on This Premium Report : https://www.coherentmarketinsights.com/insight/request-discount/213

By Company Profile, Product Image and Specification, Product Application Analysis, Production Capability, Price Cost, Production Value, Contact Data is Include in this research report.

What Diabetic Neuropathy Market report offers:

The Report Answers the Following Questions:

Get Full Report Description, TOC, Table of Figures, Chart, etc. @ Diabetic Neuropathy Market

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. In the end Diabetic Neuropathy Market Report delivers a conclusion which includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors will increase the business overall.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

Read the rest here:
Diabetic Neuropathy Market Expected to accelerate the growth of the industries forecast 2020-2026 - The Daily Chronicle

Read More...

Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma – Targeted Oncology

Tuesday, September 29th, 2020

Nilanjan Ghosh, MD, PhD, a medical oncologist at Levine Cancer Institute, Atrium Health in Charlotte, NC, discussed the case of a 22-year-old patients with advanced Hodgkin lymphoma.

Targeted Oncology: What is your assessment of the patient?

GHOSH: The patients serum albumin is 4.2 g/dL, so thats an issue. The fact that she has stage IV disease, and that the white cell count was high, and the lymphocyte count was low are factors leading to an International Prognostic Score [IPS] of 4. The 5-year overall survival for high IPS, based on historical data, is not as good. I dont know if this would apply as much now, but this is what we have if we use the historical data. That suggests that she is a higher-risk patient. To be honest, the IPS has not affected treatment choice as much, at least in the United States, but well see if some of the newer treatments such as brentuximab vedotin [Adcetris] plus doxorubicin/vinblastine/dacarbazine [A+AVD] have any effect on that subgroup.

What do the National Comprehensive Cancer Network guidelines recommend for stage III or IV disease?

There are 2 treatment pathways that can be followed in patients who have stage III or IV.1 One focuses on a PET-adaptive pathway, which is ABVD [adriamycin, bleomycin, vinblastine, dacarbazine], followed by AVD [adriamycin, vinblastine, dacarbazine] or BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone]. The non-PET adaptive therapy is the other pathway and uses brentuximab vedotin and AVD or escalated BEACOPP. Escalated BEACOPP is not usually used in North America.

Which regimen was chosen in this patient?

The patient was treated with brentuximab vedotin and AVD. Interim PET scan shows a Deauville score of 3; the patient tolerated this regimen well with G-CSF support. I think most people are certainly familiar with the Deauville scoring system, so just remembering that if the uptake is less than the liver, that is considered as grade 3 response. If its uptake is moderately above or markedly above, then thats considered progressive.

What are the key findings of the ECHELON-1 study (NCT01712490)2?

ECHELON-1 evaluated brentuximab and AVD versus ABVD. The standard of care is ABVD. The most important thing to note is the dose of brentuximab, which is 1.2 mg/kg, not 1.8 mg/kg, because this is given every 2 weeks. Its mirroring when ABVD is administered.

[This was a] large study with [more than] 1200 patients. It examined patients with stage III or IV classical Hodgkin lymphoma who had relatively good performance status. The investigators did allow patients to enroll if they had measurable disease and adequate liver and renal function. There was a PET scan at the end of cycle 2; however, this was not a PET-adaptive therapy. ABVD was given for 6 cycles. There is no decrease to AVD or escalation to BEACOPP

At 3 years, the progression-free survival [PFS] rate was 83% in the treatment arm and 76% in the control arm. This is highly significant, with a P value of .005, a hazard ratio of 0.7.

Overall, subgroup analysis favors brentuximab and AVD. But the confidence intervals do cross over in some categories, especially in the regional subgroup. For some reason, ABVD seems to do better in Asia. The study, though, is not powered to determine if 1 region is better than another. So, you have to take this kind of data with a grain of salt.

Now, remember this patient was young; shes in her early 20s. In a younger age group, the A+AVD did better than ABVD. She lives in North America, so thats a region where ABVD did better. And then looking at the IPS, she had a score of 4, and thats another group in which A+AVD did better.

In general, A+AVD would probably be favored in stage IV disease. Her symptoms are associated with having extranodal sites, and in our case, the patients extranodal site was associated with the bones. Her performance status is good.

Looking at the responses in ECHELON-1, the overall response rate was 86% versus 83%, so there are small differences.

Regarding adverse effects [AEs], remember that when we think about brentuximab, we think of peripheral neuropathy. In the study, peripheral neuropathy was 67% for the treatment arm versus 42% in the ABVD arm. For diarrhea, its 27% versus 18%, and abdominal pain was slightly higher in ABVD, as well. In terms of any AEs, theyre similar; grade 3 events were more for A+AVD versus ABVD.

I will mention that initially in the protocol there was no mandate for growth factor, so most patients were treated without growth factors. There were increasing incidences of neutropenia and neutropenic fevers in the A+AVD arm. Protocol amendments were performed later and G-CSF support was introduced. It was the middle part of the program. The guidelines recommend that A+AVD should be used with G-CSF support. But the protocol for the most part didnt initiate G-CSF support except toward the end. So, we see 83 patients who [received] G-CSF support and 579 who didnt.

In terms of serious AEs, there were more associated with A+AVD. The reason I bring that up is because the majority of that protocol was already carried out without the G-CSF support. The treatment group ended up seeing more AEs and clearly there are more incidences of neuropathy with A+AVD. Drug discontinuation, however, was about the same between the groups. Deaths during treatment [were] very low, and there were more hospitalizations observed with A+AVD.

Did investigators initiate any dose delays?

Most of the dose delays were initiated because of neutropenia and febrile neutropenia. For patients who discontinued more than 1 drug because of AEs, 7% were attributed to peripheral neuropathy, which is an important AE in this treatment.

Regarding pulmonary toxicity, we would expect a bleomycin-containing regimen would have higher pulmonary toxicity. It was seen in 7% of patients with ABVD and 2% with A+AVD,

and grade 3 or more pulmonary toxicity was low in A+AVD but observed in 3% of patients with ABVD.2

How were febrile neutropenia and any neutropenia addressed in the trial?

We see a difference between patients who [received] G-CSF support versus those who didnt, regarding febrile neutropenia versus any neutropenia. In patients who developed febrile neutropenia during treatment, 11% of those who received G-CSF support experienced the AE, and 21% who did not receive G-CSF support experienced the AE.

For neutropenia any grade, 73% of patients who did not receive GCSF versus 35% of patients who did receive G-CSF support developed it. Similarly, for grade 3 or more neutropenia, 70% who did not receive G-CSF versus 29% of patients who did developed it. To me, that is the most striking observation.

In the ABVD arm, there was neutropenia observed with ABVD, and we all have had patients with ABVD where the absolute neutrophil count is low, and we still go ahead and treat. That is done in standard practice.

In terms of serious AEs, there were more serious AEs with A+AVD compared [with] ABVD, 44% versus 28%. And there were no differences in deaths.

The A+AVD regimen can cause peripheral neuropathy. But if you look at complete resolution of peripheral neuropathy, you can see that 78% of patients treated with A+AVD had complete resolution and 83% of those on ABVD had complete resolution. Patients receiving ABVD also get neuropathy primarily because of vinblastine. Improvement in neuropathy also occurred in both groups; 17% of patients had improvement, not resolution, in the A+AVD arm versus 9% in the ABVD arm. The vast majority had resolution, but many had improvement as well.

However, for ongoing neuropathy that [was] grade 1 or 2, 25% of patients in the A+AVD arm and only 11% in the ABVD group experienced this. We have to be vigilant and monitor them throughout treatment so that it doesnt get too bad, so appropriate dose reductions can be made.

The bottom line here is most neuropathy is going to go away, but there will be patients where neuropathy can persist, and that can be an annoying thing, especially for a young person. For many in long-term follow-up, theyll experience improvement in neuropathy over time, which means things are getting better, but that doesnt mean its all resolved.

References:

1. NCCN Clinical Practice Guidelines in Oncology. Hodgkin lymphoma, version 2.2020. Accessed August 26, 2020. http://bit.ly/2YAIYha

2. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkins lymphoma. N Engl J Med. 2018;378(4):331-344. doi:10.1056/NEJMoa1708984

See the original post:
Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma - Targeted Oncology

Read More...

Ever heard of Small Fiber Neuropathy? Call the Ahn Clinic for a natural treatment – Yahoo News

Tuesday, September 29th, 2020

The Daily Beast

Everyone knows that live television isnt easy. Anything can go wrongfrom a faulty connection, a verbal slip-up, or, as was the case on Tuesday mornings Fox & Friends, Rudy Giuliani bellowing insane conspiracy theories at the nation with no obvious way to stop him.Its always a risk to allow Giuliani to share his wildly unpredictable stream of consciousness live. The man who was named Time magazines Person of the Year for 2001 has long been reduced to sharing the latest Trumpist conspiracy theories on any cable news channel that has the budget to cover any possible subsequent defamation lawsuits.This time, his F&F hosts looked on with visible horror in their eyes as Giuliani shared his completely baseless belief that Joe Biden is suffering from dementia. If you have the time, its worth watching the clip at least three times so you can see each of the hosts panicking in their own unique way as the former New York City mayor rambles on and on.> On Fox & Friends, Rudy Giuliani says Joe Biden "has dementia. There's no doubt about it. I've talked to doctors. ... The president's quite right to say maybe he's taken adderall." The hosts get visibly uncomfortable. pic.twitter.com/2Ma7DKNBpS> > Bobby Lewis (@revrrlewis) September 29, 2020With a mischievous cackle, Giuliani began: The man [Biden] has dementia. Theres no doubt about it. Ive talked to doctors. Ive had them look at a hundred different tapes of his five years ago and today. Trying his very best to shut Giuliani down, host Steve Doocy interjected that Bidens team have said the Democrat has no serious medical problems.Giuliani then made an extraordinary noise at Doocy that can best be typed as Oowughawughawugh, before continuing: He cant recite the Pledge of Allegiance and hes fine? He was in the Senate for 160 years? I mean, he cant do the prologue to the... to the... con... to the... uh... Constitution of the United States or the Declaration of Independence, any of them.Getting louder and increasingly excited about his armchair diagnosis, Giuliani went on: He cant do NUMBERS. Wow, are the numbers screwed up. He actually displays symptoms that two gerontologists told me are classic symptoms of middle level dementia. Doocy and co-host Ainsley Earhardt both responded to that claim by softly saying: Right. The third host, Brian Kilmeade, can just be seen blinking rapidly.Fox News Lobotomizes Its Brain Room, Cuts Fact-Based JournalismNevertheless, Giuliani persisted. Thats when [Biden] does that I pledge allegiance to the United States... uh... uh... um... I think, hes done that twice, said the ex mayor. Thats a classic symptom in the DSM-V, its the fifth symptom, of dementia, hes got eight of the 10.Then, seemingly remembering that he was on the show to talk about tonights presidential debate, he went on: Look, that isnt the debate. He can get through it. I think the president is quite right to say maybe hes taken Adderall or some kind of attention deficit disorder thing.As Giuliani began pulling prescription medicine brands out of the air, Doocy had finally had enough and told him firmly: None of us are doctors, that is your opinion. Giuliani fought back, saying it was actually the opinion of some very professional-sounding doctors that he knows.But the game was up. Kilmeade, in his first verbal interjection of the entire exchange, said with exasperation: We can stay away from that. Earhardt then moved on to pick Giulianis brain on the Supreme Court.This particular line of attack is one that Giulianiwhose work as President Trumps lawyer and top dirt-digger on Hunter and Joe Biden kicked off a chain of events that got his client impeached last yearhas enthusiastically embraced as one of his primary functions now for Team Trump.Shortly before midnight on Monday night, Giuliani started texting The Daily Beast to say that Trump did great in recent White House debate prep (for which the president said on Sunday that Giuliani and former New Jersey governor Chris Christie took part), and to rail against Biden as a senile, broken down old crook whos supposedly suffering from dementia and needs ADD drugs to get through the Tuesday debate. The Trump attorney also claimed that someone had told him how stupid Biden was in law school.Giuliani also mentioned late Monday evening that hed be flying with Trump on Air Force One on Tuesday and would be at the Cleveland debate. Asked about what kinds of questions he peppered the president with during the prep, the former New York City mayor replied, It really doesnt work like that with him. Its much more of a discussion rather than a rehearsal. Plus you are dealing with a very smart, very alert human being not a senile old man.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

More:
Ever heard of Small Fiber Neuropathy? Call the Ahn Clinic for a natural treatment - Yahoo News

Read More...

Global Diabetic Neuropathy Treatment Market by Business Development, Innovation and Top Companies Forecast 2020-2025 – seaview road

Tuesday, September 29th, 2020

GlobalDiabetic Neuropathy TreatmentMarket 2020is a fresh specialized intelligence report published byMarkets and Research.Bizwhich comprehensively analyzes the scope of growth of the market that can be expected during the forecast period from the year 2020 to 2025. The report tracks the latest market dynamics, such as driving factors, restraining factors. The report provides market size (value and volume), market share, growth rate by types, applications. The report contains an ability to help the decision-makers in the most important market that has played a significantly important role in making a progressive impact on the globalDiabetic Neuropathy Treatmentindustry. The trends that are expected to be successful during the forecast period due to the growth of the market are covered. It includes a detailed overview of the specific industry, several aspects, product definitions, the prevailing industry landscape, different market segments, as well as market development trends and industrial channels, new expenditure projects.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketsandresearch.biz/sample-request/10143

The report covers a number of the players in the market, including:Abbott, Roche, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Lupin, Glenmark, Depomed, Astellas, Pfizer,

Key Players Analysis:

The report focuses on global major leading industry players of the globalDiabetic Neuropathy Treatmentmarket providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue, and contact information. The report covers all their information such as historic and future trends, market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information. The report identifies the strengths and weaknesses of different companies along with the opportunities and the threats that they face from different directions. The different advancements in manufacturing technology are also listed.

READ FULL REPORT:https://www.marketsandresearch.biz/report/10143/global-diabetic-neuropathy-treatment-market-2020-by-manufacturers-countries-type-and-application-forecast-to-2025

The Report Wraps:

The report explains each market section depending on the product, application, geographical region, competitive market share. GlobalDiabetic Neuropathy Treatmentmarket size approximates, forecasts for the said frame of time are estimated and given in this report. Competitive analysis of crucial market manufacturers, trends, company profiles, strategies has been provided. It features factual information, insights, market date backed by statistics of industry.

Reasons To Buy The Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@marketsandresearch.bizWeb:www.marketsandresearch.biz

Follow this link:
Global Diabetic Neuropathy Treatment Market by Business Development, Innovation and Top Companies Forecast 2020-2025 - seaview road

Read More...

Neurophth Therapeutics’ Treatment of Leber’s Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by US FDA – BioSpace

Tuesday, September 29th, 2020

NEWARK, Del., Sept. 24, 2020 /PRNewswire/ --Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary Optic Neuropathy associated with ND4 mutation.

Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited mitochondrial disease, characterized by acute or subacute, painless vision loss or even loss simultaneously or sequentially, accompanied by central visual field defect and color vision impairment with poor prognosis. It was first reported by German scholar Leber in 1871. It affects about 1-9:100,000 people worldwide. LHON is one of the blinding diseases. The disease mainly occurs in young- and middle-aged men. Currently, there is no effective treatment for LHON. About 70% - 90% of LHON is caused by ND4 mutation of harboring a point mutation at nucleotide 11778 associated with a G-to-A transition. With the development of NR082, AAV-based gene therapy of LHON becomes possible.

"Due to the lack of effective treatment, the quality of life of LHON patients associated with ND4 mutation is very poor, and a huge unmet medical needs have not been fulfilled," said Dr. Alvin Luk, Chief Executive Officer at Neurophth. "NR082 is the first candidate drug developed by Neurophth. It uses recombinant adeno-associated virus serotype 2 to deliver the genetically modified ND4 gene (rAAV2-ND4). After a single intravitreal injection, the gene is translated and expressed in cells, which effectively supplements the function loss caused by endogenous mutation. Through this gene therapy, the electron transport function of mitochondrial respiratory chain was maintained, and the increase of ATP synthesis restored the normal function of mitochondria, which in turn improved the sensory function of the retinal ganglion cells and improved the visual acuity of LHON patients."

Luk added, "the significance of orphan drug designation is that regulators recognize the unmet medical needs of rare diseases like LHON. The recognition of NR082 will reduce the R&D investment to a certain extent and accelerate the progress of clinical trials and marketing registration. Furthermore, Neurophth is committed to fundamentally solve the causes and change the quality of life of patients through a single treatment of gene therapy."

Professor Bin Li, Founder, Chairman and Chief Scientific Officer at Neurophth, said: "NR082 has been granted as orphan drug by U.S. FDA, which further strengthens our focus on gene therapy for rare ophthalmic diseases, and develops more drugs for treatment of ocular genetic diseases, bringing hope to patients with ocular genetic diseases in the world".

*FDA grants orphan drug designation to drugs and biological products designed to safely and effectively treat, diagnose, or prevent rare diseases or conditions affecting less than 200,000 people in the US. According to the Orphan Drug Act of FDA, Orphan Drug Designation (ODD) provides opportunities for grant funding, fast approval channel, and some incentives, such as waiver of New Drug Application (NDA) fees, tax credits for clinical trial expenses and exemption for prescription drug users' fees as well as the products are entitled to a seven-year of market exclusivity and will not be affected by patents.

About NR082 (rAAV2-ND4; NFS-01 Project)

LHON disease is caused by mutations in mitochondrial DNA 11778, 14484 or 3460. ND4 gene of 11778 G>A mutation is the main pathological factor, which exists in 55-70% of European and American patients and 90% of Chinese patients. NR082 (NFS-01 project) is an innovative candidate drug for ophthalmic AAV-based gene therapy. It uses AAV2 vector to express human ND4 gene in the retinal ganglion cells to repair optic neuropathy caused by 11778 G>A mutation.

As early as 2011, Professor Bin Li's team started the world's first LHON gene therapy investigator-initiated trial (IIT) with this candidate drug. Nine subjects who participated in the clinical trial have been followed up for up to 8 years with no serious adverse reactions, and 5 of them have significant improvement in their vision. This result is the longest follow-up record of gene therapy in the world, which has already been published in the Scientific Report, EBioMedicine and Ophthalmology journals, and has fully proven the long-term safety, effectiveness, and durability of AAV gene therapy in clinical settings.

After the gratifying results of the first study, Professor Li's team conducted a more comprehensive IIT clinical study from 2017 to 2018, with 159 subjects (including 10 subjects from Argentina), which is the largest clinical trial in the entire gene therapy in the world. Among those, 143 of the patients has completed the 12-month follow-up and 56.6% showed a significant BCVA (best-corrected visual acuity improved by at least 0.3 LogMAR) improvement. No serious adverse reaction was found. In May 2020, at the 23rd online annual meeting of the American Society for Gene and Cell Therapy (ASGCT) and the online annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Neurophth presented these two clinical research data on the treatment of LHON with NR082 (NFS-01 project of rAAV2-ND4), demonstrating the international advanced level of this research in the field of gene therapy.

Following the positive results of these two IIT trials, Neurophth is actively preparing the China/U.S. IND (Investigational New Drug) applications, and plans to carry out the registration clinical Phase 1/2/3 registration trial to evaluate the safety, efficacy and durability of NR082.

About Neurophth

As a clinical-stage R & D company, Neurophth is committed to exploring and developing new therapies for global patients with ophthalmic diseases. With the help of the mature AAV ophthalmic gene therapy technology platform and the deep understanding of the ophthalmology field by the founding team for decades, Neurophth has established a rich, robust product pipeline, including more than 10 research projects for various ophthalmic diseases, such as dominant hereditary optic atrophy, optic nerve injury diseases, vascular retinopathy, etc., and gradually expanded from rare to common ophthalmic diseases. Additionally, the company is preparing to build a GMP commercial production platform for gene therapy drugs accordance with the international quality standards, and plans to build an ophthalmic gene therapy transformational excellence center, aiming to become a global leader in gene therapy in ophthalmology to benefit patients all over the world.

Prospect of Gene Therapy in Ophthalmology

Inherited retinal diseases (IRDs) have long been regarded as an ideal disease area for gene therapy, because most of the gene mutations leading to the disease have been identified (more than 200 gene defects are associated with the most common IRDS). The eye is, to some extent, an immune privilege. Clinical trials have shown that gene therapy using adeno-associated virus (AAV) or lentivirus (LV) vectors in the eye does not cause systemic side effects and does not cause significant immune responses. The most common IRDs were Retinitis Pigmentosa (RP), Achromatopsia color blindness (ACHM), Leber Hereditary Optic Neuropathy (LHON), Leber Congenital Amaurosis (LCA), Stargardt disease and X-linked Retinoschisis (XLRS).

To date, only one ophthalmic AAV gene therapy product has been approved in the world, namely the first AAV2 gene therapy voretigene neparvovec-rzyl (LUXTURNA; Spark Therapeutics) approved by FDA in December 2017 to treat IRD caused by RPE65 double allele mutation in adult or pediatric patients. The approval of LUXTURNAhas brought confidence and hope to the global ophthalmic gene therapy field. Public information disclosed that at least 20-30 kinds of gene therapy for ophthalmic diseases are in the research and development stage, and the international representative companies include Applied Genetic Technologies Corporation and Meira GTX, and new companies represented by Neurophth have also begun to enter the international stage of ophthalmic gene therapy.

References

Contact:Dr. Alvin LukAlvin.Luk@neurophth.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-was-granted-orphan-drug-designation-by-us-fda-301138001.html

SOURCE Neurophth Therapeutics, Inc.

Excerpt from:
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by US FDA - BioSpace

Read More...

Impact of COVID-19 on Diabetic Peripheral Neuropathy Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Reata…

Tuesday, September 29th, 2020

Diabetic Peripheral Neuropathy Treatment Market research report is the new statistical data source added by A2Z Market Research.

Diabetic Peripheral Neuropathy Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Diabetic Peripheral Neuropathy Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=315642

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Reata Pharmaceuticals Inc, KPI Therapeutics Inc, Achelios Therapeutics Inc, ViroMed Co Ltd, Novaremed Ltd, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Medifron DBT Co Ltd, Relief Therapeutics Holding AG, Celgene Corp

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Diabetic Peripheral Neuropathy Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Diabetic Peripheral Neuropathy Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=315642

The cost analysis of the Global Diabetic Peripheral Neuropathy Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Table of Contents

Global Diabetic Peripheral Neuropathy Treatment Market Research Report 2020 2026

Chapter 1 Diabetic Peripheral Neuropathy Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Diabetic Peripheral Neuropathy Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=315642

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Visit link:
Impact of COVID-19 on Diabetic Peripheral Neuropathy Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Reata...

Read More...

Page 11234..10..»


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick